CDK4 and liposarcoma: Recent studies in other CDK4-amplified sarcomas, such as dedifferentiated liposarcoma and synovial sarcoma, have demonstrated synergistic antitumor effects and prognostic significance of CDK4/6 inhibition (25, 26).